Impact of Dapagliflozin Adjunctive Therapy on the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 2-5: A systematic review and meta-analysis.
Albuminuria
Chronic Kidney Disease
Dapagliflozin
Glomerular Filtration Rate
SGLT2 Inhibitors
Type 2 Diabetes Mellitus
Journal
Sultan Qaboos University medical journal
ISSN: 2075-0528
Titre abrégé: Sultan Qaboos Univ Med J
Pays: Oman
ID NLM: 101519915
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
received:
03
07
2023
revised:
04
09
2023
revised:
25
09
2023
accepted:
24
10
2023
medline:
5
9
2024
pubmed:
5
9
2024
entrez:
5
9
2024
Statut:
ppublish
Résumé
This meta-analysis investigated efficacy of dapagliflozin as adjunctive therapy for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stages 2-5. A systematic search was conducted of selected databases for randomised controlled trials that reported the mean change in estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) from baseline. Out of 1,682 identified studies, 9 trials comprising 13,057 patients were included. A pooled estimate of 5 studies indicated that dapagliflozin did not affect eGFR; however, in 2 studies, it significantly reduced chronic eGFR decline compared to placebo (mean difference [MD] ± 2.74; 95% confidence interval [CI]: 1.55, 3.92;
Identifiants
pubmed: 39234312
doi: 10.18295/squmj.12.2023.093
pii: squmj2408-317-326
pmc: PMC11370938
doi:
Substances chimiques
dapagliflozin
1ULL0QJ8UC
Glucosides
0
Benzhydryl Compounds
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
317-326Informations de copyright
© Copyright 2024, Sultan Qaboos University Medical Journal, All Rights Reserved.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST: The authors declare no conflict of interest.